Corrigendum to 'Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology' [Int. J. Cardiol. 220 (2016) 131-136]

The authors regret that some dates of sponsor's involvement in the program were incorrectly reported in the initial published paper, therefore please consider the below corrected information: Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2014), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2017), Bayer (2009–2018), Boehringer Ingelheim (2009–2016), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2017), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2009–2018). The authors would like to apologise for any inconvenience caused.

• View at Publisher
• View at Scopus

Free Full Text ( Final Version , 159kb )

See Also

article Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology E. Ertekin (Ebru), I.M. van Hagen (Iris), A.M. Salam (Amar M.), T.P.E. Ruys (Titia), M.R. Johnson (Mark), J. Popelová (Jana), W.A. Parsonage (William A.), Z. Ashour (Zeinab), Shotan, A. (Avraham), Oliver, J.M. (José M.), et al. G.R. Veldtman (Gruschen R.), R. Hall (Ruth) and J.W. Roos-Hesselink (Jolien)